336 Stock Overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Hepion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.45 |
| 52 Week High | US$17.93 |
| 52 Week Low | US$1.08 |
| Beta | 1.62 |
| 1 Month Change | -39.08% |
| 3 Month Change | -12.65% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 336 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 26.1% | 0.9% | -1.0% |
| 1Y | n/a | -27.7% | 2.0% |
Return vs Industry: Insufficient data to determine how 336 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 336 performed against the German Market.
Price Volatility
| 336 volatility | |
|---|---|
| 336 Average Weekly Movement | 19.2% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 336's share price has been volatile over the past 3 months.
Volatility Over Time: 336's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 22 | John Cavan | www.hepionpharma.com |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. Fundamentals Summary
| 336 fundamental statistics | |
|---|---|
| Market cap | €7.42m |
| Earnings (TTM) | -€45.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 336 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 336 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$48.93m |
| Earnings | -US$48.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 336 perform over the long term?
See historical performance and comparison